FEATURED COMPANIES
- Amgen Inc.
- Bayer
- Bristol-Myers Squibb
- Celgene Corporation
- Dendreon Pharmaceuticals
- ELI Lilly and Company
- MORE
The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to reach USD 152.83 billion by 2024.
Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, opportunities, and challenges. The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market. However, the high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.
Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five-year survival rates as compared to other cancer treatment options available in the market.
Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, the significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.
An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and the Asia Pacific region. The large share of this region is mainly attributed to the factors such as rising incidence of cancer globally, growing adoption of immunotherapy for cancer treatment, rising investments in collaboration and mergers, and enhancement in the drug development process owing to the development of bioinformatics. Furthermore, the regulatory bodies such as US FDA and European Commission are specially focusing on the research of cancer immunotherapy due to the advantages of this therapy compared with other treatment options. The faster drug approval in the cancer immunotherapy is also responsible for the growth of this market.
The key players profiled in the global cancer immunotherapy market research report are F. Hoffmann-La Roche, Celgene Corporation, Bristol-Myers Squibb, Merck & Co., Inc., Amgen Inc., ELI Lilly and Company, Janssen Global Services, LLC (Johnson and Johnson), Novartis, Pfizer, Inc., Gilead Sciences, Inc., Dendreon Pharmaceuticals, and Bayer among others.
Scope of the Report
- Market by Product
- Monoclonal Antibodies
- Checkpoint Inhibitors
- Immunomodulators
- Vaccines
- Cell Therapy
Market by Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Multiple Myeloma
- Other Cancer Types
Market by End User
- Hospitals
- Clinics & Others
Market by Geography
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
FEATURED COMPANIES
- Amgen Inc.
- Bayer
- Bristol-Myers Squibb
- Celgene Corporation
- Dendreon Pharmaceuticals
- ELI Lilly and Company
- MORE
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer Incidence
4.2.2. Growing Adoption of Immunotherapy over other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to Initiate the Clinical Trials
4.5.2. Complexities of Tumor
5. Industry Insights
5.1. Key Industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China’s Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. Opdivo and Keytruda: Major Products in Cancer Immunotherapy Market
6. Cancer Immunotherapy Market, by Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint Inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies
7. Cancer Immunotherapy Market, by Application
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types
8. Cancer Immunotherapy Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others
9. Cancer Immunotherapy Market, by Region
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments
11. Company Profiles
11.1. Astrazeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis International AG
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene Corporation
12. Appendix
12.1. Questionnaire
List of Tables
Table 1 Major Cancer Immunotherapy Drugs Approved (2015–2017)
Table 2 Recent Developments in Cancer Immunotherapy Market in China
Table 3 Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 4 Cancer Immunotherapy Market, by Country/Region, 2016–2024 ($Million)
Table 5 Key Monoclonal Antibodies Approved for Cancer Immunotherapy
Table 6 Key Conjugated Antibodies for Cancer Immunotherapy
Table 7 Monoclonal Antibodies Market, by Country/Region, 2016–2024 ($Million)
Table 8 Major FDA Approved PD-1 and PD-L1 Inhibitors
Table 9 Checkpoint Inhibitors Market, by Country/Region, 2016–2024 ($Million)
Table 10 Key Immunomodulators Available in the Market
Table 11 Immunomodulators Market, by Country/Region, 2016–2024 ($Million)
Table 12 Cancer Vaccines Market, by Country/Region, 2016–2024 ($Million)
Table 13 Cell Therapies Market, by Country/Region, 2016–2024 ($Million)
Table 14 Cancer Immunotherapy Market, by Application, 2016–2024 ($Million)
Table 15 Lung Cancer Immunotherapy Market, by Country/Region, 2016–2024 ($Million)
Table 16 Breast Cancer Immunotherapy Market, by Country/Region, 2016–2024 ($Million)
Table 17 Colorectal Cancer Immunotherapy Market, by Country/Region, 2016–2024 ($Million)
Table 18 Melanoma Immunotherapy Market, by Country/Region, 2016–2024 ($Million)
Table 19 Prostate Cancer Immunotherapy Market, by Country/Region, 2016–2024 ($Million)
Table 20 Multiple Myeloma: Recent Developments from Leading Players
Table 21 Multiple Myeloma Immunotherapy Market, by Country/Region, 2016–2024 ($Million)
Table 22 Other Cancer Immunotherapy Market, by Country/Region, 2016–2024 ($Million)
Table 23 Cancer Immunotherapy Market, by End User, 2016–2024 ($Million)
Table 24 Hospital Market for Cancer Immunotherapy, by Country/Region, 2016–2024 ($Million)
Table 25 Clinics and Others Market for Cancer Immunotherapy, by Country/Region, 2016–2024 ($Million)
Table 26 North America Cancer Immunotherapy Market, by Country, 2016–2024 ($Million)
Table 27 North America: Market, by Type, 2016–2024 ($Million)
Table 28 North America: Market, by Application, 2016–2024 ($Million)
Table 29 North America: Market, by End User, 2016–2024 ($Million)
Table 30 Leading Sites of New Cancer Cases (2017)
Table 31 Us: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 32 Us: Market, by Application, 2016–2024 ($Million)
Table 33 Us: Market, by End User, 2016–2024 ($Million)
Table 35 Canada: Cancer Immunotherapy Market, by Application, 2016–2024 ($Million)
Table 36 Canada: Market, by End User, 2016–2024 ($Million)
Table 37 Europe Cancer Immunotherapy Market, by Country, 2016–2024 ($Million)
Table 38 Europe: Market, by Type, 2016–2024 ($Million)
Table 39 Europe: Market, by Application, 2016–2024 ($Million)
Table 40 Europe: Market, by End User, 2016–2024 ($Million)
Table 41 Germany: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 42 Germany: Market, by Application, 2016–2024 ($Million)
Table 43 Germany: Market, by End User, 2016–2024 ($Million)
Table 44 France: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 45 France: Market, by Application, 2016–2024 ($Million)
Table 46 France: Market, by End User, 2016–2024 ($Million)
Table 47 U.K.: Funding By National Cancer Research Institute, 2012
Table 48 U.K.: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 49 U.K.: Market, by Application, 2016–2024 ($Million)
Table 50 U.K.: Market, by End User, 2016–2024 ($Million)
Table 51 Italy: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 52 Italy: Market, by Application, 2016–2024 ($Million)
Table 53 Italy: Market, by End User, 2016–2024 ($Million)
Table 54 Spain: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 55 Spain: Market, by Application, 2016–2024 ($Million)
Table 56 Spain: Market, by End User, 2016–2024 ($Million)
Table 57 Rest of Europe: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 58 Rest of Europe: Market, by Application, 2016–2024 ($Million)
Table 59 Rest of Europe: Market, by End User, 2016–2024 ($Million)
Table 60 Asia Pacific Cancer Immunotherapy Market, by Country, 2016–2024 ($Million)
Table 61 Asia Pacific: Market, by Type, 2016–2024 ($Million)
Table 62 Asia Pacific: Market, by Application, 2016–2024 ($Million)
Table 63 Asia Pacific: Market, by End User, 2016–2024 ($Million)
Table 64 China: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 65 China: Market, by Application, 2016–2024 ($Million)
Table 66 China: Market, by End User, 2016–2024 ($Million)
Table 67 Japan: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 68 Japan: Market, by Application, 2016–2024 ($Million)
Table 69 Japan: Market, by End User, 2016–2024 ($Million)
Table 70 India: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 71 India: Market, by Application, 2016–2024 ($Million)
Table 72 India: Market, by End User, 2016–2024 ($Million)
Table 73 Rest of APAC: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 74 Rest of APAC: Market, by Application, 2016–2024 ($Million)
Table 75 Rest of APAC: Market, by End User, 2016–2024 ($Million)
Table 76 Latin America: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 77 Latin America: Market, by Application, 2016–2024 ($Million)
Table 78 Latin America: Market, by End User, 2016–2024 ($Million)
Table 79 Middle East and Africa: Cancer Immunotherapy Market, by Type, 2016–2024 ($Million)
Table 80 Middle East and Africa: Market, by Application, 2016–2024 ($Million)
Table 81 Middle East and Africa: Market, by End User, 2016–2024 ($Million)
Table 82 Key Products: Monoclonal Antibodies
Table 83 Key Products: Checkpoint Inhibitors
Table 84 Key Products: Immunomodulators
Table 85 Key Products: Vaccines
Table 86 Key Products: Cell Therapies
List of Figures
Figure 1 Global Cancer Immunotherapy Market, 2016–2024 ($ Million)
Figure 2 Cancer Immunotherapy: Global Market Outlook, by Type 2018 Vs. 2024
Figure 3 Cancer Immunotherapy: Global Market Outlook, by Application 2018 Vs. 2024
Figure 4 Cancer Immunotherapy: Global Market Outlook, by End User 2018 Vs. 2024
Figure 5 Cancer Immunootherapy: Regional Market Outlook, 2018 Vs. 2024
Figure 6 Market Overview: Cancer Immunotherapy Market
Figure 7 Global Cancer Incidence and Mortality (2018)
Figure 8 Cancer Therapy Deals Distribution (2012-2016)
Figure 9 Clinical Trials Check Point Inhibitors (2017)
Figure 10 R&D Expenditure of Major Players in Cancer Immunotherapy Market (2015 Vs 2017)
Figure 11 Cancer Incidence by Region (2018)
Figure 12 Per Capita Healthcare Expenditure In Selected Emerging Countries ($)
Figure 13 Improvement in 5 Year Survival Rates: Personalized Immunotherapy
Figure 14 Biopharmaceutical Companies Are Committed To Advancing Personalized Medicines
Figure 15 Clinical Trials for Cancer Immunotherapy in Combination
Figure 16 Opdivo (BMS) Vs Keytruda (Merck)
Figure 17 Distribution of Approved Monoclonal Antibody Drugs, by Indication
Figure 18 Number of Combination Studies for PD-1/PD-L1 Mab
Figure 19 Lung Cancer Statistics (2018)
Figure 20 PD-1 & PD-L1: New Clinical Trials and Average Enrolment Per New Trial
Figure 21 Breast Cancer Statistics (2018)
Figure 22 Colorectal Cancer Statistics (2018)
Figure 23 Melanoma Incidence Rate, 2016 (Per 100,000)
Figure 24 Prostate Cancer Statistics (2018)
Figure 25 Us Healthcare Spending ($ Billion)
Figure 26 Us Healthcare Spending ($ Billion)
Figure 27 Us: Country Health Profile (Cancer)
Figure 28 Canada: Cancer Incidence, by Type (2015)
Figure 29 Canada: Geriatric Population (Million)
Figure 30 Canada: Country Profile (Cancer)
Figure 31 Europe: Highest Share of Geriatric Population, 2010-2017
Figure 32 Germany: Country Health Profile (Cancer)
Figure 33 France: Country Health Profile
Figure 34 U.K.: Country Health Profile
Figure 35 Italy: Country Health Profile
Figure 36 Spain: Share of Clinical Trials in Oncology
Figure 37 Spain: Country Health Profile
Figure 38 Rest of Europe: Key Indicators
Figure 39 China: Clinical Trials (2012–2016)
Figure 40 China: Country Health Profile
Figure 41 Japan: Country Health Profile
Figure 42 India: Country Health Profile
Figure 43 Australia: Country Health Profile
Figure 44 Brazil: Country Health Profile
Figure 45 Key Strategy Adopted By Major Players in Market: Approvals
Figure 46 Market Share Analysis of Key Players
Figure 47 Cancer Immunotherapy: Competitive Benchmarking
LOADING...
- Amgen Inc.
- Bayer
- Bristol-Myers Squibb
- Celgene Corporation
- Dendreon Pharmaceuticals
- ELI Lilly and Company
- F. Hoffmann-La Roche
- Gilead Sciences Inc.
- Janssen Global Services LLC
- Merck & Co. Inc.
- Novartis
- Pfizer Inc.
![Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/7029/7029337_60px_jpg/immunooncology_market_by_type_[mab_naked.jpg)
![Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/8116/8116579_60px_jpg/regenerative_medicine_market_by_type_[cellbased_immunotherapy_and_cell_therapy_allogeneic_and_autologous_products_tissue_engineering_gene_therapy]_applications_wounds_and_dermal_musculoskeletal_oncology_region_global_forecast_to_2024.jpg)